| pubmed-article:19217320 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19217320 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:19217320 | lifeskim:mentions | umls-concept:C0085243 | lld:lifeskim |
| pubmed-article:19217320 | lifeskim:mentions | umls-concept:C0021641 | lld:lifeskim |
| pubmed-article:19217320 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:19217320 | lifeskim:mentions | umls-concept:C0167117 | lld:lifeskim |
| pubmed-article:19217320 | lifeskim:mentions | umls-concept:C0205332 | lld:lifeskim |
| pubmed-article:19217320 | lifeskim:mentions | umls-concept:C0205146 | lld:lifeskim |
| pubmed-article:19217320 | lifeskim:mentions | umls-concept:C1514485 | lld:lifeskim |
| pubmed-article:19217320 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19217320 | pubmed:dateCreated | 2010-4-26 | lld:pubmed |
| pubmed-article:19217320 | pubmed:abstractText | The notion of combining immunomodulatory agents with the incretin exendin-4 (Ex-4) has seen considerable favor as a potential therapy for the reversal of type 1 diabetes in man. While the addition of Ex-4 provides modest improvement to the effectiveness of immunological-based monotherapies in reversing hyperglycemia in the nonobese diabetic (NOD) mouse, the mechanism of action underlying this effect remains controversial and formed the basis for this investigation. | lld:pubmed |
| pubmed-article:19217320 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19217320 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19217320 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19217320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19217320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19217320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19217320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19217320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19217320 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19217320 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19217320 | pubmed:issn | 1873-460X | lld:pubmed |
| pubmed-article:19217320 | pubmed:author | pubmed-author:XueSongS | lld:pubmed |
| pubmed-article:19217320 | pubmed:author | pubmed-author:Campbell-Thom... | lld:pubmed |
| pubmed-article:19217320 | pubmed:author | pubmed-author:SchatzDesmond... | lld:pubmed |
| pubmed-article:19217320 | pubmed:author | pubmed-author:ParkerMatthew... | lld:pubmed |
| pubmed-article:19217320 | pubmed:author | pubmed-author:WasserfallCli... | lld:pubmed |
| pubmed-article:19217320 | pubmed:author | pubmed-author:AtkinsonMark... | lld:pubmed |
| pubmed-article:19217320 | pubmed:author | pubmed-author:HallerMichael... | lld:pubmed |
| pubmed-article:19217320 | pubmed:author | pubmed-author:McGrailKieran... | lld:pubmed |
| pubmed-article:19217320 | pubmed:author | pubmed-author:McGrailSeanS | lld:pubmed |
| pubmed-article:19217320 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19217320 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:19217320 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19217320 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19217320 | pubmed:pagination | 163-7 | lld:pubmed |
| pubmed-article:19217320 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:meshHeading | pubmed-meshheading:19217320... | lld:pubmed |
| pubmed-article:19217320 | pubmed:articleTitle | Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area. | lld:pubmed |
| pubmed-article:19217320 | pubmed:affiliation | Department of Pathology, University of Florida, Gainesville, FL 32610, USA. | lld:pubmed |
| pubmed-article:19217320 | pubmed:publicationType | Journal Article | lld:pubmed |
